Leerink Partnrs Issues Optimistic Estimate for LLY Earnings

Eli Lilly and Company (NYSE:LLY) – Stock analysts at Leerink Partnrs raised their FY2027 earnings per share (EPS) estimates for Eli Lilly and Company in a research note issued to investors on Monday, November 10th. Leerink Partnrs analyst D. Risinger now anticipates that the company will post earnings of $40.88 per share for the year, up from their prior estimate of $38.91. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Eli Lilly and Company’s current full-year earnings is $23.48 per share.

A number of other equities research analysts also recently issued reports on LLY. Deutsche Bank Aktiengesellschaft decreased their price objective on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a research report on Monday, August 11th. HSBC increased their price target on Eli Lilly and Company from $700.00 to $800.00 in a report on Wednesday, October 1st. Daiwa America lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Sunday, August 17th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Eli Lilly and Company in a research report on Wednesday, October 8th. Finally, Wall Street Zen raised shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 1st. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average price target of $981.89.

Eli Lilly and Company Stock Up 3.0%

Shares of NYSE:LLY opened at $1,018.28 on Wednesday. The company has a market cap of $962.67 billion, a price-to-earnings ratio of 66.55, a PEG ratio of 1.21 and a beta of 0.43. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,022.42. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The company has a 50-day moving average price of $815.33 and a 200 day moving average price of $778.16.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. The firm had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. Eli Lilly and Company’s revenue for the quarter was up 53.9% compared to the same quarter last year. During the same period last year, the firm posted $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be paid a $1.50 dividend. This represents a $6.00 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 29.35%.

Hedge Funds Weigh In On Eli Lilly and Company

A number of hedge funds have recently added to or reduced their stakes in LLY. Wealth Preservation Advisors LLC purchased a new stake in shares of Eli Lilly and Company in the 1st quarter worth $27,000. Sumitomo Mitsui Financial Group Inc. purchased a new stake in Eli Lilly and Company in the second quarter worth about $27,000. Evolution Wealth Management Inc. purchased a new stake in Eli Lilly and Company in the second quarter worth about $29,000. Steph & Co. grew its holdings in Eli Lilly and Company by 290.0% during the 3rd quarter. Steph & Co. now owns 39 shares of the company’s stock worth $30,000 after acquiring an additional 29 shares in the last quarter. Finally, Financial Gravity Companies Inc. purchased a new position in Eli Lilly and Company during the 2nd quarter valued at about $31,000. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.